禾盛平台 娱乐

    <sub id="5vrrv"><dfn id="5vrrv"><mark id="5vrrv"></mark></dfn></sub>

    <sub id="5vrrv"></sub><thead id="5vrrv"><var id="5vrrv"><mark id="5vrrv"></mark></var></thead>

      <address id="5vrrv"><listing id="5vrrv"></listing></address>

      <form id="5vrrv"></form>

      <address id="5vrrv"><listing id="5vrrv"></listing></address><sub id="5vrrv"><var id="5vrrv"><mark id="5vrrv"></mark></var></sub>

          <sub id="5vrrv"><var id="5vrrv"><ins id="5vrrv"></ins></var></sub><sub id="5vrrv"><dfn id="5vrrv"><mark id="5vrrv"></mark></dfn></sub>

          <sub id="5vrrv"><dfn id="5vrrv"></dfn></sub>

          <sub id="5vrrv"><var id="5vrrv"><output id="5vrrv"></output></var></sub>

          <form id="5vrrv"><nobr id="5vrrv"></nobr></form>

          <sub id="5vrrv"><dfn id="5vrrv"><mark id="5vrrv"></mark></dfn></sub>

            <address id="5vrrv"><dfn id="5vrrv"></dfn></address>

            <address id="5vrrv"><dfn id="5vrrv"><mark id="5vrrv"></mark></dfn></address>

            KE, XUE

            Release date:2016-06-21  Release:


            KE, XUE

            Professor of Pharmaceutics

            Director of Jiangsu province public technology service center of nanodrug preparation and evaluation

            School of Pharmacy

            Phone: 86-25-83271035

            Email: kexue@vip.sina.com

            Research Summary

            Professor KE’s research focuses on the development of novel drug delivery systems and pharmaceutical technologies of biomacromolecule drugs and hydrophobic drugs.She has recently published about 20 SCI papers and takes on projects from Natural Science Foundation of China, State Project For Essential Drug Research and Development, etc.

            Professor KE’s research also focuses on the formulation development of generic drugs. She has achieved technical transformation to industries up to forty pieces and obtained two pieces of Clinical Trial Permission of the first type of new drug.

            Education

            1999/09—2003/06

            Ph.D., Pharmaceutics,China Pharmaceutical University

            1994/09—1997/06

            M.S.,  Pharmaceutics,China Pharmaceutical University

            1990/09-1994/06

            B.S.,   Pharmaceutics,China Pharmaceutical University

            Academic Experience

            1997- present     
            Professor of Pharmaceutics, China Pharmaceutical University

            2007/01—2010/12

            Post Doc, Department of Life Sciences, Nanjing University

            2013/01—2013/06

            Drug Evaluation Scientist, State Center for Drug Evaluation

            Awards and Honors

            2011       New Century Excellent Researcher Award Program from Ministry of Education of China

            2011       “333 high-level personnel training project  Young leaders in science and technology of Jiangsu Province

            2007        Second in Science and Technology Progress Award of Jiangsu Province

            Publications

            [1] J.L. Tian, M.M. Han, Y.Wang, K.Qian, X. Ke*,T.Y.Ci,Reduction-responsive modification-induced higherefficiency for attenuation of tumor metastasis oflow molecular weight heparin functionalizedliposomes, RSC Advances, 6(2016), 49250.

            [2] Y. Chen, J. Peng, M. Han, M. Omar, D. Hu, X. Ke*, N. Lu*, A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis, Journal of Drug Targeting, 23 (2015) 335-346.

            [3] O. Mezghrani, Y. Tang, X. Ke*, Y. Chen, D. Hu, J. Tu*, L. Zhao, N. Bourkaib, Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin, International Journal of Pharmaceutics, 478 (2015) 553-568.

            [4] J. Tian, L. Wang, L. Wang, X. Ke*, A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects, Drug Delivery, 21 (2014) 553-559.

            [5] Y. Zhang, R. Luo, Y. Chen, X. Ke*, D. Hu, M. Han, Application of Carrier and Plasticizer to Improve the Dissolution and Bioavailability of Poorly Water-Soluble Baicalein by Hot Melt Extrusion, Aaps Pharmscitech, 15 (2014) 560-568.

            [6] J. Li, H. Xu, X. Ke*, J. Tian, The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid, Journal of Drug Targeting, 20 (2012) 467-473.

            [7] J.L. Tian, C. Tian, X. Ke*, Comparative evaluation of a co-processed self-lubricating excipient LubriTose SD as a direct compression vehicle, Journal of Drug Delivery Science and Technology, 22 (2012) 562-567.

            [8] X. Dong, X. Ke*, Z. Liao, The microstructure characterization of meloxicam microemulsion and its influence on the solubilization capacity, Drug Development and Industrial Pharmacy, 37 (2011) 894-900.

            [9] X. Ke*, J.H. Bei, Y. Zhang, J. Li, In vitro and in vivo evaluation of sanguinarine liposomes prepared by a remote loading method with three different ammonium salts, Pharmazie, 66 (2011) 258-263.

            [10] J.L. Tian, X. Ke*, Z. Chen, C.J. Wang, Y. Zhang, T.C. Zhong, Melittin liposomes surface modified with poloxamer 188: in vitro characterization and in vivo evaluation, Die Pharmazie, 66 (2011) 362-367.


              <sub id="5vrrv"><dfn id="5vrrv"><mark id="5vrrv"></mark></dfn></sub>

              <sub id="5vrrv"></sub><thead id="5vrrv"><var id="5vrrv"><mark id="5vrrv"></mark></var></thead>

                <address id="5vrrv"><listing id="5vrrv"></listing></address>

                <form id="5vrrv"></form>

                <address id="5vrrv"><listing id="5vrrv"></listing></address><sub id="5vrrv"><var id="5vrrv"><mark id="5vrrv"></mark></var></sub>

                    <sub id="5vrrv"><var id="5vrrv"><ins id="5vrrv"></ins></var></sub><sub id="5vrrv"><dfn id="5vrrv"><mark id="5vrrv"></mark></dfn></sub>

                    <sub id="5vrrv"><dfn id="5vrrv"></dfn></sub>

                    <sub id="5vrrv"><var id="5vrrv"><output id="5vrrv"></output></var></sub>

                    <form id="5vrrv"><nobr id="5vrrv"></nobr></form>

                    <sub id="5vrrv"><dfn id="5vrrv"><mark id="5vrrv"></mark></dfn></sub>

                      <address id="5vrrv"><dfn id="5vrrv"></dfn></address>

                      <address id="5vrrv"><dfn id="5vrrv"><mark id="5vrrv"></mark></dfn></address>

                      冠亚体育

                      万福彩票是官方网站

                      皇冠足球足球比分

                      彩客网官方网站

                      银河娱乐场澳门官方

                      吉利彩的网页版

                      同乐城在线娱乐官网

                      qy8千亿国际欢迎您

                      2019彩票平台下载